CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's senior management team will conduct a fireside chat on Tuesday, April 8, 2025, at 12:45 p.m. ET.
The presentation will be accessible through a live webcast on the company's investor relations website under the 'Events & Presentations' section. Interested parties can access the replay of the webcast, which will remain available for 14 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRSP declined 4.47%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ZUG, Switzerland and BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Needham Healthcare Conference 2025?
How can investors watch CRSP's Needham Conference presentation?
How long will CRSP's Needham Conference presentation replay be available?
What type of presentation will CRSP deliver at the Needham Healthcare Conference?
